Several new medications are transforming blood sugar treatment, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide being highlighted leading choices. Retatrutide, a double GIP and GLP-1 site stimulant, shows substantial fat reduction and enhanced glucose control. Cagrillintide, a GLP-1 agonist, is presently in research trials, suggesting